{"id":"W4283692377","doi":"10.1177/13524585221102584","title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Innosuisse - Schweizerische Agentur für Innovationsförderung; EMD Serono; Multiple Sclerosis International Federation; Allergan; Shionogi; National Research Foundation; Janssen Pharmaceuticals; Atara Biotherapeutics; European Committee for Treatment and Research in Multiple Sclerosis; Bristol-Myers Squibb; CSL Behring; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; TG Therapeutics; Pfizer; Bayer HealthCare; European Commission; Sanofi; MedDay Pharmaceuticals; National Multiple Sclerosis Society","keywords":"Medicine; Adverse effect; Internal medicine; Tolerability; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005710124,0.0003983215,0.001360678,0.0009414984,0.0005851761,0.0001392175,0.001082474,0.0001360484,0.0001131096],"category_scores_gemma":[0.005586183,0.0003354985,0.0002419386,0.001536621,0.0002833436,0.000360962,0.001638577,0.001523421,0.00000446877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004802744,"about_ca_system_score_gemma":0.0002829983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008363618,"about_ca_topic_score_gemma":0.0008995078,"domain_scores_codex":[0.9934423,0.001257126,0.00188518,0.0007348239,0.001806928,0.0008736278],"domain_scores_gemma":[0.9958452,0.002020863,0.000641346,0.0008319353,0.000314398,0.0003462569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1766478,0.005038156,0.3087126,0.0001824498,0.0003384668,0.0001102461,0.01908666,0.0008521574,0.3485449,0.00001443372,0.001471131,0.1390011],"study_design_scores_gemma":[0.18661,0.001977978,0.8046743,0.001620399,0.00007524883,0.00005740637,0.002666967,0.001033129,0.0008823982,0.000006835203,0.0001350098,0.0002603632],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932446,0.00126158,0.00009089948,0.001023408,0.0007819276,0.003425355,0.00009837167,0.00001862036,0.00005517479],"genre_scores_gemma":[0.996067,0.001959322,0.00121934,0.0002436159,0.0001663586,0.0001807693,0.00002281553,0.00007268504,0.00006804049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4959617,"threshold_uncertainty_score":0.9999097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1887642141103295,"score_gpt":0.3523233674991694,"score_spread":0.1635591533888399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}